Immunocore (NASDAQ:IMCR) Reaches New 1-Year High – Here’s What Happened

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) reached a new 52-week high on Friday . The stock traded as high as $40.71 and last traded at $39.93, with a volume of 5771 shares. The stock had previously closed at $40.22.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Morgan Stanley increased their target price on shares of Immunocore from $34.00 to $36.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. Guggenheim started coverage on shares of Immunocore in a research note on Thursday, September 18th. They issued a “neutral” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a report on Wednesday, October 22nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a report on Wednesday, October 8th. Finally, Wall Street Zen raised Immunocore from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Immunocore has a consensus rating of “Moderate Buy” and an average target price of $61.00.

Immunocore Trading Down 3.2%

The firm has a market capitalization of $1.97 billion, a price-to-earnings ratio of -68.16 and a beta of 0.77. The company has a quick ratio of 5.97, a current ratio of 6.00 and a debt-to-equity ratio of 0.99. The firm’s 50 day moving average is $35.06 and its 200 day moving average is $34.23.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.32. The company had revenue of $103.69 million for the quarter, compared to analysts’ expectations of $137.29 million. Immunocore had a negative return on equity of 7.67% and a negative net margin of 7.70%.The firm’s revenue was up 29.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.17 earnings per share. Equities analysts forecast that Immunocore Holdings PLC Sponsored ADR will post -0.94 earnings per share for the current year.

Insider Buying and Selling at Immunocore

In related news, insider David M. Berman sold 22,532 shares of Immunocore stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $35.67, for a total value of $803,716.44. The sale was disclosed in a legal filing with the SEC, which is available at this link. 10.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its position in shares of Immunocore by 51.6% in the 3rd quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock valued at $33,000 after acquiring an additional 311 shares in the last quarter. DNB Asset Management AS lifted its holdings in shares of Immunocore by 6.4% in the third quarter. DNB Asset Management AS now owns 8,116 shares of the company’s stock valued at $295,000 after purchasing an additional 488 shares in the last quarter. Virtus Investment Advisers LLC lifted its holdings in shares of Immunocore by 5.3% in the second quarter. Virtus Investment Advisers LLC now owns 12,472 shares of the company’s stock valued at $391,000 after purchasing an additional 625 shares in the last quarter. Orion Porfolio Solutions LLC boosted its position in shares of Immunocore by 4.5% in the second quarter. Orion Porfolio Solutions LLC now owns 23,965 shares of the company’s stock worth $752,000 after buying an additional 1,031 shares during the period. Finally, Assetmark Inc. grew its holdings in shares of Immunocore by 3.7% during the second quarter. Assetmark Inc. now owns 34,958 shares of the company’s stock valued at $1,097,000 after buying an additional 1,248 shares in the last quarter. 84.50% of the stock is owned by hedge funds and other institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.